180 Life Sciences EBITDA
Qual é o EBITDA de 180 Life Sciences?
O EBITDA de 180 Life Sciences Corp. é -$16.63
Qual é a definição de EBITDA?
O EBITDA é o lucro de uma empresa antes de juros, impostos, depreciação e amortização e é uma medida contábil calculada com base no lucro líquido de uma empresa, subtraído antes das despesas de juros, impostos, depreciação e amortização, como imagem da lucratividade operacional corrente de uma empresa.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA de empresas na Setor Health Care em NASDAQ em comparação com 180 Life Sciences
O que 180 Life Sciences faz?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Empresas com ebitda semelhantes a 180 Life Sciences
- Siyata Mobile tem EBITDA de -$16.69
- Galway Metals tem EBITDA de -CAD$16.69
- Galway Metals tem EBITDA de -CAD$16.69
- Amicus Therapeutics Inc tem EBITDA de -$16.68
- Bionomics tem EBITDA de -AUD$16.68
- Redx Pharma Plc tem EBITDA de -£16.65
- 180 Life Sciences tem EBITDA de -$16.63
- F-Secure Oyj tem EBITDA de -€16.57
- Aleafia Health Inc tem EBITDA de -CAD$16.57
- Clarus Corp tem EBITDA de -$16.56
- Ioneer tem EBITDA de -AUD$16.55
- Limeade tem EBITDA de -$16.52
- American Resources tem EBITDA de -$16.52